NASDAQ:LIFE
aTyr Pharma Stock News
$1.60
-0.0200 (-1.23%)
At Close: Apr 19, 2024
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
06:20pm, Tuesday, 09'th May 2023
Atyr Pharma (LIFE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.44 per share a year ago.
aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript
05:12pm, Friday, 10'th Mar 2023
aTyr Pharma, Inc. (NASDAQ:LIFE ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Ashlee Dunston - Director, Investor Relations & Corporate Communications Sanjay Shukla -
Where aTyr Pharma Stands With Analysts
03:01pm, Friday, 10'th Mar 2023 Benzinga
Analysts have provided the following ratings for aTyr Pharma (NASDAQ:LIFE) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
0
0
0
Las
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
10:15pm, Thursday, 09'th Mar 2023 Zacks Investment Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
09:00pm, Thursday, 09'th Mar 2023 GlobeNewswire Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan.
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
06:19pm, Thursday, 09'th Mar 2023
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma to Present at March Investor Conferences
01:00pm, Wednesday, 08'th Mar 2023 GlobeNewswire Inc.
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tR
aTyr Pharma to Present at March Investor Conferences
08:00am, Wednesday, 08'th Mar 2023
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
05:00pm, Friday, 17'th Feb 2023 Zacks Investment Research
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
01:33pm, Friday, 17'th Feb 2023
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
aTyr Pharma Announces Commencement of Public Offering of Common Stock
09:11pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRN
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Friday, 18'th Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRN
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
10:15pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript
08:32pm, Thursday, 10'th Nov 2022
aTyr Pharma, Inc. (NASDAQ:LIFE ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Ashlee Dunston - Director, IR & Corporate Communications Sanjay Shukla - President &
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
06:48pm, Thursday, 10'th Nov 2022
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
